Thus, FOXM1 may be a marker for GSCs with growth potential and a prediction biomarker for survival and may thus be useful for optimizing VEGF-targeted antiangiogenic therapy including neoBev in newly diagnosed GBM. The gene discussed is FOXM1; the disease is glioblastoma.